S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NYSE:EW

Edwards Lifesciences Stock Forecast, Price & News

$83.65
-0.82 (-0.97 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$83.38
Now: $83.65▼
$84.78
50-Day Range
$71.69
MA: $81.16▼
$85.61
52-Week Range
$51.51
Now: $83.65▼
$88.00
Volume1.70 million shs
Average Volume3.54 million shs
Market Capitalization$52.13 billion
P/E Ratio66.92
Dividend YieldN/A
Beta0.92
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.76 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:EW
Previous Symbol
CUSIP28176E10
CIK1099800
Webwww.edwards.com
Phone949-250-2500
Employees13,900

Debt

Debt-to-Equity Ratio0.14
Current Ratio3.52
Quick Ratio2.61

Price-To-Earnings

Trailing P/E Ratio66.92
Forward P/E Ratio43.80
P/E Growth2.75

Sales & Book Value

Annual Sales$4.35 billion
Price / Sales11.99
Cash Flow$2.02 per share
Price / Cash Flow41.42
Book Value$6.76 per share
Price / Book12.37

Profitability

EPS (Most Recent Fiscal Year)$1.86
Net Income$1.05 billion
Net Margins18.18%
Return on Equity29.00%
Return on Assets18.10%

Miscellaneous

Outstanding Shares623,248,000
Market Cap$52.13 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$83.65
-0.82 (-0.97 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

How has Edwards Lifesciences' stock price been impacted by Coronavirus (COVID-19)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EW stock has increased by 27.1% and is now trading at $83.65.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Edwards Lifesciences?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Edwards Lifesciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Edwards Lifesciences?

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Edwards Lifesciences.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings results on Wednesday, October, 21st. The medical research company reported $0.51 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.45 by $0.06. The medical research company earned $1.14 billion during the quarter, compared to analysts' expectations of $1.08 billion. Edwards Lifesciences had a net margin of 18.18% and a return on equity of 29.00%.
View Edwards Lifesciences' earnings history.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY20 earnings guidance on Wednesday, October, 21st. The company provided earnings per share guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.84.

What price target have analysts set for EW?

20 analysts have issued 1 year target prices for Edwards Lifesciences' stock. Their forecasts range from $51.67 to $105.00. On average, they expect Edwards Lifesciences' stock price to reach $87.72 in the next year. This suggests a possible upside of 4.9% from the stock's current price.
View analysts' price targets for Edwards Lifesciences.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decrease in short interest in the month of October. As of October 30th, there was short interest totaling 4,980,000 shares, a decrease of 29.7% from the October 15th total of 7,080,000 shares. Based on an average daily volume of 2,540,000 shares, the short-interest ratio is presently 2.0 days.
View Edwards Lifesciences' Short Interest.

Who are some of Edwards Lifesciences' key competitors?

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all competitors.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 67, Pay $3.64M)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 53, Pay $1.42M)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 58, Pay $1.36M)
  • Mr. Larry L. Wood, Corp. VP of Transcatheter Aortic Valve Replacement (Age 54, Pay $1.46M)
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer
  • Mark Wilterding, VP of Investor Relations
  • Mr. Arnold A. Pinkston, Corp. VP & Gen. Counsel (Age 61)
  • Mr. Dirksen J. Lehman, Corp. VP of Public Affairs
  • Ms. Christine Z. McCauley, Corp. VP of HR (Age 55)
  • Mr. Robert W. A. Sellers, VP & Corp. Controller

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.47%), State Street Corp (4.29%), Sands Capital Management LLC (1.94%), Jackson Square Partners LLC (0.97%), UBS Asset Management Americas Inc. (0.92%) and Fisher Asset Management LLC (0.83%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, First Trust Advisors LP, State of Tennessee Treasury Department, Nuveen Asset Management LLC, AQR Capital Management LLC, State Street Corp, BlackRock Inc., and Point72 Asset Management L.P.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was purchased by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, CIBC Private Wealth Group LLC, Jupiter Asset Management Ltd., AustralianSuper Pty Ltd, Jennison Associates LLC, UBS Asset Management Americas Inc., Raymond James & Associates, and Envestnet Asset Management Inc..
View insider buying and selling activity for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $83.65.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $52.13 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.